Capital Insight Partners LLC Sells 90 Shares of Eli Lilly and Company (NYSE:LLY)

Capital Insight Partners LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,424 shares of the company’s stock after selling 90 shares during the period. Capital Insight Partners LLC’s holdings in Eli Lilly and Company were worth $1,262,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Strategic Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.7% during the third quarter. Strategic Advisors LLC now owns 1,633 shares of the company’s stock worth $1,447,000 after purchasing an additional 28 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management lifted its holdings in Eli Lilly and Company by 748.9% during the 3rd quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,073 shares of the company’s stock worth $2,722,000 after buying an additional 2,711 shares in the last quarter. Brendel Financial Advisors LLC boosted its position in Eli Lilly and Company by 5.9% in the 3rd quarter. Brendel Financial Advisors LLC now owns 2,192 shares of the company’s stock valued at $1,942,000 after buying an additional 122 shares during the last quarter. Modus Advisors LLC increased its stake in shares of Eli Lilly and Company by 32.3% in the 3rd quarter. Modus Advisors LLC now owns 479 shares of the company’s stock valued at $424,000 after buying an additional 117 shares during the period. Finally, SS&H Financial Advisors Inc. raised its position in shares of Eli Lilly and Company by 14.6% during the third quarter. SS&H Financial Advisors Inc. now owns 959 shares of the company’s stock worth $850,000 after acquiring an additional 122 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Truist Financial raised their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Barclays raised their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, Bank of America upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Price Performance

Shares of LLY opened at $910.69 on Friday. The stock has a 50 day simple moving average of $906.72 and a 200 day simple moving average of $850.80. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a market capitalization of $865.55 billion, a PE ratio of 112.15, a P/E/G ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Sell-side analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.